Liquid biopsy: an innovative and reliable method for detecting not only somatic, but also germline mutations in patients with colorectal and non-small cell lung carcinoma

Nelly Miteva-Marchevaa Department of Pediatrics and Medical Genetics, Faculty of Medicine, Medical University – Plovdiv, Plovdiv, Bulgaria;b Department of Medical Genetics, University Hospital “Sveti Georgi” – Plovdiv, Plovdiv, BulgariaCorrespondence[email protected]
View further author information

Hristo Ivanova Department of Pediatrics and Medical Genetics, Faculty of Medicine, Medical University – Plovdiv, Plovdiv, Bulgaria;b Department of Medical Genetics, University Hospital “Sveti Georgi” – Plovdiv, Plovdiv, BulgariaView further author information

Veselin Popovc Department of Clinical Oncology, Faculty of Medicine, Medical University – Plovdiv, Plovdiv, Bulgaria;d Clinic of Radiation Oncology, University Hospital “Sveti Georgi” – Plovdiv, Plovdiv, BulgariaView further author information

Gabriela Raychevac Department of Clinical Oncology, Faculty of Medicine, Medical University – Plovdiv, Plovdiv, Bulgaria;e Clinic of Medical Oncology, University Hospital “Sveti Georgi” – Plovdiv, Plovdiv, BulgariaView further author information

Zhanet Grudeva-Popovac Department of Clinical Oncology, Faculty of Medicine, Medical University – Plovdiv, Plovdiv, Bulgaria;f Clinic of Clinical Hematology, University Hospital “Sveti Georgi” – Plovdiv, Plovdiv, BulgariaView further author information

Vili Stoyanovaa Department of Pediatrics and Medical Genetics, Faculty of Medicine, Medical University – Plovdiv, Plovdiv, Bulgaria;b Department of Medical Genetics, University Hospital “Sveti Georgi” – Plovdiv, Plovdiv, BulgariaView further author information

Liquid biopsy: an innovative and reliable method for detecting not only somatic, but also germline mutations in patients with colorectal and non-small cell lung carcinoma

Table 1. A targeted pharmacogenetics panel for screening of 484 genes in cancer patients.

Table 2. CRC patients: treatment, adverse effects and gene variants.

Table 3. NSCLC patients: treatment, adverse effects and gene variants.

Table 4. Genotype distributions for all analysed gene variants in patients with CRC and NSCLC.

Table 5. Associations between the genotypes of a particular SNP with occurrence of adverse effects after therapy in patients with CRC and NSCLC.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Liquid biopsy: an innovative and reliable method for detecting not only somatic, but also germline mutations in patients with colorectal and non-small cell lung carcinoma

Figures & data

Table 1. A targeted pharmacogenetics panel for screening of 484 genes in cancer patients.

Table 2. CRC patients: treatment, adverse effects and gene variants.

Table 3. NSCLC patients: treatment, adverse effects and gene variants.

Table 4. Genotype distributions for all analysed gene variants in patients with CRC and NSCLC.

Table 5. Associations between the genotypes of a particular SNP with occurrence of adverse effects after therapy in patients with CRC and NSCLC.

Data availability statement

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date